PL1937673T3 - Pochodne imidazolu jako inhibitory TAFI-A - Google Patents

Pochodne imidazolu jako inhibitory TAFI-A

Info

Publication number
PL1937673T3
PL1937673T3 PL06792327T PL06792327T PL1937673T3 PL 1937673 T3 PL1937673 T3 PL 1937673T3 PL 06792327 T PL06792327 T PL 06792327T PL 06792327 T PL06792327 T PL 06792327T PL 1937673 T3 PL1937673 T3 PL 1937673T3
Authority
PL
Poland
Prior art keywords
tafia
inhibitors
imidazole derivatives
imidazole
derivatives
Prior art date
Application number
PL06792327T
Other languages
English (en)
Inventor
Christopher Kallus
Holger Heitsch
Volkmar Wehner
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PL1937673T3 publication Critical patent/PL1937673T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL06792327T 2005-10-15 2006-09-30 Pochodne imidazolu jako inhibitory TAFI-A PL1937673T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005049385A DE102005049385A1 (de) 2005-10-15 2005-10-15 Imidazolderivate als Inhibitoren von TAFIa
PCT/EP2006/009500 WO2007045339A1 (de) 2005-10-15 2006-09-30 Imidazolderivate als inhibitoren von tafi-a
EP06792327.6A EP1937673B1 (de) 2005-10-15 2006-09-30 Imidazolderivate als inhibitoren von tafi-a

Publications (1)

Publication Number Publication Date
PL1937673T3 true PL1937673T3 (pl) 2016-03-31

Family

ID=37733974

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06792327T PL1937673T3 (pl) 2005-10-15 2006-09-30 Pochodne imidazolu jako inhibitory TAFI-A

Country Status (12)

Country Link
US (1) US8044208B2 (pl)
EP (1) EP1937673B1 (pl)
JP (1) JP5266053B2 (pl)
CY (1) CY1117379T1 (pl)
DE (1) DE102005049385A1 (pl)
DK (1) DK1937673T3 (pl)
ES (1) ES2558874T3 (pl)
HU (1) HUE026577T2 (pl)
PL (1) PL1937673T3 (pl)
PT (1) PT1937673E (pl)
SI (1) SI1937673T1 (pl)
WO (1) WO2007045339A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2262783A2 (en) * 2008-02-21 2010-12-22 Sanofi-Aventis Covalently binding imaging probes
AU2009310841A1 (en) * 2008-10-29 2010-05-06 Taisho Pharmaceutical Co., Ltd. Compounds having TAFIa inhibitory activity
KR20130006620A (ko) 2010-03-18 2013-01-17 다이이찌 산쿄 가부시키가이샤 시클로프로판카르복실산 유도체
SG10201502026XA (en) 2010-03-18 2015-05-28 Daiichi Sankyo Co Ltd Cycloalkyl-substituted imidazole derivative
KR101799429B1 (ko) 2010-05-03 2017-11-21 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
JP6130383B2 (ja) 2011-09-30 2017-05-17 エンドゥ ファーマシューティカルズ，インコーポレイティド ピリジン誘導体
JP6105594B2 (ja) 2011-09-30 2017-03-29 エンドゥ ファーマシューティカルズ，インコーポレイティド 癌処置用ｃｙｐ１７阻害剤としてのイミダゾール誘導体
RU2015156612A (ru) * 2013-06-10 2017-07-17 Санофи Макроциклические производные мочевины в качестве ингибиторов tafia, их получение и их применение в качестве фармацевтических средств
KR20220119653A (ko) 2019-12-20 2022-08-30 테나야 테라퓨틱스, 인코포레이티드 플루오로알킬-옥사디아졸 및 이의 용도
US20240252502A1 (en) 2021-05-04 2024-08-01 Tenaya Therapeutics, Inc. Hdac6 inhibitors for treatment of metabolic disease and hfpef

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1311488E (pt) * 2000-08-17 2009-12-30 Pfizer Ltd Imidazóis substituídos utilizados como inibidores de tafia
WO2003013526A1 (en) * 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
CA2472239A1 (en) * 2002-01-22 2003-07-31 Pfizer Inc. 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases

Also Published As

Publication number Publication date
EP1937673A1 (de) 2008-07-02
CY1117379T1 (el) 2017-04-26
SI1937673T1 (sl) 2016-02-29
JP5266053B2 (ja) 2013-08-21
EP1937673B1 (de) 2015-10-21
PT1937673E (pt) 2016-02-08
DK1937673T3 (en) 2016-01-25
US8044208B2 (en) 2011-10-25
US20080262028A1 (en) 2008-10-23
HUE026577T2 (hu) 2016-06-28
ES2558874T3 (es) 2016-02-09
DE102005049385A1 (de) 2007-04-19
WO2007045339A1 (de) 2007-04-26
JP2009511516A (ja) 2009-03-19

Similar Documents

Publication Publication Date Title
IL194582A0 (en) Condensed imidazole derivatives as aromatase inhibitors
IL198640A0 (en) Hydantoin derivatives used as mmp inhibitors
IL197955A0 (en) Imidazolone and imidazolidinone derivatives as 11b-hsd1 inhibitors for diabetes
IL198247A0 (en) Indazole derivatives useful as l-cpt1 inhibitors
IL200047A0 (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
IL196590A0 (en) Acrylamide derivatives as fab i inhibitors
IL194755A0 (en) Pyrimidine derivatives as pi3k inhibitors
IL193482A0 (en) Hydantoin based kinase inhibitors
EP2336123A4 (en) HETEROCYCLIC COMPOUND AS INHIBITOR OF PROTEIN KINASE
ZA201005166B (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
ZA200904175B (en) Imidazole derivatives as kinesin spindle protein inhibitors (EG-5)
ZA201007431B (en) Imidazolidinone derivatives as 11b-hsd1 inhibitors
IL178672A0 (en) Imidazole derivatives used as tafia inhibitors
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
ZA200705068B (en) Hydantoin derivatives useful as metalloproteinase inhibitors
PT2104497E (pt) Derivados de ureia e sulfamida enquanto inibidores de tafia
SI1937673T1 (sl) Imidazolovi derivati kot inhibitorji TAFIa
IL193981A0 (en) Novel heterocyclic nf-kb inhibitors
ZA200905235B (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
ZA200806993B (en) Hydantoin based kinase inhibitors
HK1122805A (en) Condensed imidazole derivatives as aromatase inhibitors
HK1156319A (en) Heterocyclic derivatives as hdac inhibitors
HK1139312A (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
HK1160386A (en) Heterocyclic kinase inhibitors